Table 2.
Baseline clinical characteristics of group A (current topical therapy + CIT/HOMO one tablet a day, in the first period) and group B (current topical therapy alone, in the first period).
|
Overall group
(57 patients) |
Group A
(26 patients) |
Group B
(31 patients) |
p-value | |
|---|---|---|---|---|
| Visual acuity (decimals, Snellen) | 9.5 ± 1.2 | 9.4 ± 1.1 | 9.5 ± 1.2 | 0.54 |
| IOP (mmHg) | 14.6 ± 2.5 | 14.2 ± 2.1 | 15.1 ± 2.7 | 0.07 |
| Visual field | ||||
| VFI (%) | 91.8 ± 8.3 | 90.7 ± 9 | 92.9 ± 7.7 | 0.21 |
| MD (decibels) | −3.5 ± 3.3 | −3.9 ± 3.6 | −3 ± 3.1 | 0.16 |
| PSD (dB) | 4.1 ± 3 | 4.4 ± 3.2 | 3.9 ± 2.9 | 0.4 |
| Pattern electroretinogram (PERG) -transient PERG | ||||
| Central | ||||
| Amplitude Amp-p50 (μV) | 2.7± 2.1 | 2.5± 2.3 | 2.5± 1.9 | 0.29 |
| Latency Lat-p50 (msec) | 59.4± 8.2 | 60.2± 10.9 | 58.7± 4.7 | 0.34 |
| Amplitude Amp-n95 (μV) | 1.2± 2.5 | 1.6± 2.5 | 0.9± 2.4 | 0.17 |
| Latency Lat-n95 (msec) | 106.3± 22.9 | 107.8 ± 23.5 | 105± 22.4 | 0.53 |
| Inferior | ||||
| Amplitude Amp-p50 (μV) | 1.4 ± 1.3 | 1.1 ± 1.1 | 1.6 ± 1.3 | 0.07 |
| Latency Lat-p50 (msec) | 59.9 ± 8.4 | 60.5 ± 8.9 | 59.5 ± 8.2 | 0.61 |
| Amplitude Amp-n95 (μV) | 0.7 ± 1.1 | 1 ± 1.2 | 0.6 ± 0.9 | 0.08 |
| Latency Lat-n95 (msec) | 110.6 ± 10.5 | 111.6 ± 10.8 | 109.9 ± 10.4 | 0.51 |
| Superior | ||||
| Amplitude Amp-p50 (μV) | 1.1 ± 1.8 | 0.8 ± 2.3 | 1.3 ± 1.2 | 0.22 |
| Latency Lat-p50 (msec) | 60.3 ± 6.5 | 60.2 ± 5.8 | 60.3 ± 7.1 | 0.92 |
| Amplitude Amp-n95 (μV) | 1 ± 1.7 | 1 ± 2.3 | 1 ± 1.1 | 0.88 |
| Latency Lat-n95 (msec) | 111.1 ± 14.5 | 110.9 ± 16.4 | 111.1 ± 13 | 0.95 |
| PERG steady state (Hz) | ||||
| Central | ||||
| Amplitude | 1.8 ± 1.3 | 1.9 ± 1.4 | 1.7 ± 1.2 | 0.62 |
| Latency | 114 ± 29.5 | 108.2 ± 31.8 | 118.5 ± 27.4 | 0.14 |
| Inferior | ||||
| Amplitude | 1.2 ± 1 | 1.1 ± 0.9 | 1.3 ± 1.1 | 0.65 |
| Latency | 129.1 ± 9.7 | 130.5 ± 14.2 | 128.5 ± 7.1 | 0.56 |
| Superior | ||||
| Amplitude | 1.2 ± 1.1 | 1.6 ± 1.4 | 1 ± 1 | 0.17 |
| Latency | 130.5 ± 7.4 | 130.5 ± 8.5 | 130.5 ± 6.9 | 0.97 |
| Quality Of life (NEI-VFQ25) | ||||
| General health | 64 ± 15 | 65.9 ± 12.3 | 62.5 ± 16.9 | 0.39 |
| General vision (GV) | 68.1 ± 11 | 69.4 ± 11.8 | 67.1 ± 10.4 | 0.62 |
| Ocular Pain–OP | 79.4 ± 18.2 | 78.4 ± 19.9 | 80.2 ± 17 | 0.61 |
| Near Activities–NA | 79.5 ± 19.2 | 81.4 ± 19.8 | 77.9 ± 18.8 | 0.45 |
| Distance Activities–DA | 89.2 ± | 89.7 ± 16.9 | 88.7 ± 9.5 | 0.51 |
| Vision Specific Social Functioning–VSSF | 94.3 ± 12.5 | 91.8 ± 15.8 | 96.4 ± 8.6 | 0.18 |
| Vis Spec Mental Health–VSMH | 77.8 ± 16.3 | 75.5 ± 15.2 | 79.8 ± 17.1 | 0.49 |
| Vis Spec Role Difficulties–VSRD | 91.4 ± 16.7 | 93.7 ± 16.3 | 89.5 ± 17.1 | 0.85 |
| Vis Spec Dependency–VSD | 94.6 ± 15.1 | 92 ± 19.6 | 96.8 ± 9.8 | 0.76 |
| Driving–D | 80.1 ± 23.6 | 82.8 ± 22 | 77.9 ± 24.9 | 0.54 |
| Color vision–CV | 95.2 ± 12 | 92.3 ± 15.4 | 97.6 ± 7.5 | 0.48 |
| Peripheral Vision–PV | 89 ± 18.3 | 90.4 ± 18.8 | 87.9 ± 18.1 | 0.56 |
All values are expressed as mean ± SD.